ACP3 (prostatic acid phosphatase)

Ongoing clinical trials and approved products targeting ACP3 (prostatic acid phosphatase), in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

4ongoing imaging trials

0approved products

Target note

Full name: Prostatic acid phosphatase (ACP3)
Nature: Prostatic enzyme, one form of which is exposed at the cell surface.
Normal expression: Prostate.
Value: A target complementary to PSMA, especially in tumors with low PSMA.
Approaches: [68Ga]Ga-OncoACP3.
Indications explored: Prostate cancer (early phases).
Points of caution: Preliminary data.

Ongoing imaging trials · 4Open in the radar →

Trial	Phase	Status	Sponsor	Countries
[68Ga]Ga-OncoACP3NCT07830212 · Prostate – localised / recurrence	Phase 2	Not yet recruiting	Yong He	1
SWAP · [68Ga]Ga-OncoACP3NCT07600554 · Prostate – other	Phase 1	Recruiting	Philogen S.p.A.	1
[68Ga]Ga-OncoACP3NCT07559201 · Prostate – other	No phase	Recruiting	Guilin Medical University, China	1
[68Ga]Ga-OncoACP3NCT07242014 · Prostate – other	No phase	Recruiting	The First Affiliated Hospital of Xiamen University	1

Cite this page

ACP3 (prostatic acid phosphatase). Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/acp3-prostatic-acid-phosphatase/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.